Insilico Medicine executives are set to share their expertise in artificial intelligence (AI)-driven drug discovery at prominent healthcare and investment conferences in Shanghai and Dubai, highlighting the growing role of AI in pharmaceutical research, development, and global business partnerships.
November 3 | China Healthcare Summit, Shanghai
Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to speak at the China Healthcare Summit in Shanghai. Her keynote address, scheduled for 16:45 on November 3, will form part of a panel titled “The Commoditization Trap: Who Wins When Everyone Has the Same AI?”
Dr. Wang will examine how pharmaceutical companies can maintain a competitive edge as generative AI tools and models become increasingly accessible. Drawing on Insilico Medicine’s Pharma.AI platform, engineering practices, and industry partnerships, she will highlight the importance of proprietary data, automated experimental feedback loops, specialised AI models, and tangible drug development outcomes.
She will also share insights into emerging cross-border transactions and partnership opportunities in AI-driven drug discovery.
Jointly organised by BioCentury, BayHelix, and McKinsey & Company, the China Healthcare Summit is a leading international platform connecting pharmaceutical executives, investors, and innovators. Its discussions cover licensing deals, NewCo models, regulatory developments, investment trends, and opportunities across Asian life sciences markets.
November 4–5 | Future Healthcare Investment Market, Shanghai
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, will deliver a keynote address at the 2026 Future Healthcare Investment Market (FHIM) annual conference on November 4.
His presentation will focus on AI-driven small-molecule drug discovery, particularly how generative chemistry and automated experimental feedback loops can accelerate the development process from target identification to preclinical candidate (PCC) selection.
Drawing on Insilico Medicine’s clinical-stage drug development programmes, Dr. Ren will demonstrate how AI capabilities can translate into valuable pipeline assets and commercially viable opportunities. He will also discuss strategies for creating value through technological differentiation and business development partnerships amid a more cautious global investment climate.
Held at the Shanghai International Convention Center, FHIM brings together international investors, pharmaceutical business development leaders, and biotechnology innovators to explore cross-border licensing, co-development, technology valuation, and investment opportunities.
Also Read :- SIEF Unveils 2026 China-Arab Investment Report and Announces World Bank Partnership at Investopia